Mario Sznol
YOU?
Author Swipe
View article: Improving immunotherapy responses by dual inhibition of macrophage migration inhibitory factor and PD-1
Improving immunotherapy responses by dual inhibition of macrophage migration inhibitory factor and PD-1 Open
Macrophage migration inhibitory factor (MIF) is an upstream regulatory cytokine that is associated with advanced disease and poor outcomes in multiple cancer types, including melanoma. We investigated whether anti-MIF therapy could enhance…
View article: A Phase 3 trial of fianlimab + cemiplimab versus pembrolizumab in patients with previously untreated, unresectable, locally advanced or metastatic melanoma
A Phase 3 trial of fianlimab + cemiplimab versus pembrolizumab in patients with previously untreated, unresectable, locally advanced or metastatic melanoma Open
View article: 758 GLIMMER-01: phase 1/2 trial of a first-in-class bi-sialidase (E-602) in combination with cemiplimab in patients with PD-(L)1-resistant solid tumors
758 GLIMMER-01: phase 1/2 trial of a first-in-class bi-sialidase (E-602) in combination with cemiplimab in patients with PD-(L)1-resistant solid tumors Open
View article: 671 A first-in-human study evaluating safety, tolerability and efficacy of TEV-56278, as monotherapy and in combination with pembrolizumab in participants with locally advanced or metastatic solid tumors
671 A first-in-human study evaluating safety, tolerability and efficacy of TEV-56278, as monotherapy and in combination with pembrolizumab in participants with locally advanced or metastatic solid tumors Open
View article: Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction
Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction Open
While whole genome sequencing (WGS) of cell-free DNA (cfDNA) holds enormous promise for detection of molecular residual disease (MRD), its performance is limited by WGS error rate. Here we introduce AccuScan, an efficient cfDNA WGS technol…
View article: Clonal determinants of organotropism and survival in metastatic uveal melanoma
Clonal determinants of organotropism and survival in metastatic uveal melanoma Open
Uveal melanoma (UM), the most common intraocular primary cancer in adults, demonstrates a unique proclivity for liver metastasis. To understand the molecular underpinnings of this organotropism, we analyzed the genomic features of liver an…
View article: Immunotherapy utilization in stage IIIA melanoma: less may be more
Immunotherapy utilization in stage IIIA melanoma: less may be more Open
Background Immunotherapy agents are approved for adjuvant treatment of stage III melanoma; however, evidence for survival benefit in early stage III disease is lacking. Current guidelines for adjuvant immunotherapy utilization in stage III…
View article: Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction
Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction Open
While whole genome sequencing (WGS) of cell-free DNA (cfDNA) holds enormous promise for molecular residual disease (MRD) detection, its performance is limited by WGS error rate. Here we introduce AccuScan, an efficient cfDNA WGS technology…
View article: Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US
Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US Open
Importance While immunotherapy is being used in an expanding range of clinical scenarios, the incidence of immunotherapy initiation at the end of life (EOL) is unknown. Objective To describe patient characteristics, practice patterns, and …
View article: Interferon-stimulated neutrophils as a predictor of immunotherapy response
Interferon-stimulated neutrophils as a predictor of immunotherapy response Open
View article: A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better
A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better Open
Background Stimulating inflammatory tumor associated macrophages can overcome resistance to PD-(L)1 blockade. We previously conducted a phase I trial of cabiralizumab (anti-CSF1R), sotigalimab (CD40-agonist) and nivolumab. Our current purp…
View article: 736 A phase 1/2 open-label, dose-escalation study of ST-067, a decoy-resistant IL-18 cytokine, given as a monotherapy and with pembrolizumab in advanced solid tumor malignancies
736 A phase 1/2 open-label, dose-escalation study of ST-067, a decoy-resistant IL-18 cytokine, given as a monotherapy and with pembrolizumab in advanced solid tumor malignancies Open
Background IL-18 is an inflammatory cytokine with immuno-stimulatory activities on both the innate and adaptive immune systems. However, tumors generate an IL-18 decoy receptor (IL-18 BP), which inactivates both endogenous and exogenously …
View article: 714 Phase 1a trial of PLN-101095, an integrin αvβ8 and αvβ1 inhibitor, as monotherapy and in combination with pembrolizumab, in treatment-resistant patients with advanced or metastatic solid tumors
714 Phase 1a trial of PLN-101095, an integrin αvβ8 and αvβ1 inhibitor, as monotherapy and in combination with pembrolizumab, in treatment-resistant patients with advanced or metastatic solid tumors Open
Background Analyses of transforming growth factor-β (TGF-β) expression in tumors treated with immune checkpoint inhibitors (ICIs) suggest that in the tumor microenvironment may play a role in poor response to ICIs. PLN-101095 is a novel, o…
View article: 542 TIGIT as a potential therapeutic target in renal cell carcinoma
542 TIGIT as a potential therapeutic target in renal cell carcinoma Open
Background Despite the transformative impact of current immune checkpoint inhibitors (ICIs) targeting the PD-1 and CTLA-4 pathways on the management of advanced renal cell carcinoma (RCC), many patients still do not receive long-term benef…
View article: Determinants of overall survival in patients with metastatic uveal melanoma
Determinants of overall survival in patients with metastatic uveal melanoma Open
Background Despite improvements in the treatment of primary uveal melanoma (UM), patients with metastatic disease continue to exhibit poor survival. Methods A retrospective review of metastatic UM patients at Yale (initial cohort) and Memo…
View article: Contents
Contents Open
View article: CD-19-1510R1_Supplementary_Appendix.docx from Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
CD-19-1510R1_Supplementary_Appendix.docx from Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02) Open
Consolidated supplementary appendix: tables, figures, text plus legends
View article: Supplementary Data from A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
Supplementary Data from A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors Open
Supplementary Figures, Tables, and Methods
View article: Data from Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
Data from Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02) Open
This single-arm, phase I dose-escalation trial (NCT02983045) evaluated bempegaldesleukin (NKTR-214/BEMPEG), a CD122-preferential IL2 pathway agonist, plus nivolumab in 38 patients with selected immunotherapy-naïve advanced solid tumors (me…
View article: Data from Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
Data from Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer Open
Adenosine mediates immunosuppression within the tumor microenvironment through triggering adenosine 2A receptors (A2AR) on immune cells. To determine whether this pathway could be targeted as an immunotherapy, we performed a phase I clinic…
View article: Data from Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
Data from Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer Open
Adenosine mediates immunosuppression within the tumor microenvironment through triggering adenosine 2A receptors (A2AR) on immune cells. To determine whether this pathway could be targeted as an immunotherapy, we performed a phase I clinic…
View article: Table S3 from First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Table S3 from First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study Open
Pharmacokinetic data expressed in Cmax at each dose level in the dose escalation portion of the study.
View article: Table S1 from First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Table S1 from First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study Open
Tumor types and molecular alterations of enrolled patients
View article: Data from Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
Data from Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02) Open
This single-arm, phase I dose-escalation trial (NCT02983045) evaluated bempegaldesleukin (NKTR-214/BEMPEG), a CD122-preferential IL2 pathway agonist, plus nivolumab in 38 patients with selected immunotherapy-naïve advanced solid tumors (me…
View article: Supplementary Data from Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
Supplementary Data from Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer Open
Supplemental Appendix
View article: Table S1 from First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Table S1 from First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study Open
Tumor types and molecular alterations of enrolled patients
View article: Supplemental Material, Supplementary Figures 1 and 2, Supplemental Tables 1 - 8 from A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma
Supplemental Material, Supplementary Figures 1 and 2, Supplemental Tables 1 - 8 from A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma Open
Supplementary Figure 1: Schema of the hierarchical classifier development platform Supplementary Figure 2: Process for the simultaneous refinement of training class labels and classifier Supplementary Table 1: Association of Patient Charac…
View article: Supplementary Data from Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
Supplementary Data from Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer Open
Supplemental Appendix
View article: CD-19-1510R1_Supplementary_Appendix.docx from Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
CD-19-1510R1_Supplementary_Appendix.docx from Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02) Open
Consolidated supplementary appendix: tables, figures, text plus legends
View article: Data from A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma
Data from A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma Open
A mass spectrometry analysis was performed using serum from patients receiving checkpoint inhibitors to define baseline protein signatures associated with outcome in metastatic melanoma. Pretreatment serum was obtained from a development s…